109 filings
8-K
SIOX
Sio Gene Therapies Inc.
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
8-K
SIOX
Sio Gene Therapies Inc.
15 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
8-K
SIOX
Sio Gene Therapies Inc.
14 Feb 23
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
7:01am
8-K
SIOX
Sio Gene Therapies Inc.
14 Dec 22
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
4:04pm
8-K
SIOX
Sio Gene Therapies Inc.
10 Nov 22
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
7:03am
8-K
j0k5o532y
14 Sep 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:08pm
8-K
3edljum
11 Aug 22
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
7:05am
8-K
lun9dwog
14 Jun 22
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
7:01am
8-K
temle tlgzf
27 Apr 22
Sio Gene Therapies Provides Corporate Update
4:35pm
8-K
omgg z2bp
18 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:21pm
8-K
5cs2g4q 6e0m6sr6
11 Feb 22
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
7:02am
8-K
wythpapcp5f8ob0utp
9 Feb 22
Regulation FD Disclosure
7:00am
8-K/A
bdp18z
31 Jan 22
Submission of Matters to a Vote of Security Holders
4:18pm
8-K
499 p2ec3vrz8c
31 Jan 22
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition
4:08pm
8-K
j6l1v
25 Jan 22
Departure of Directors or Certain Officers
4:50pm
8-K
tdvty6
12 Nov 21
Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results
7:02am
8-K
5dd1qgi wwpzy
12 Nov 21
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy Program for Parkinson's Disease
12:00am
8-K
5aq4im x0
1 Nov 21
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with GM2 Gangliosidosis
7:00am
8-K
39uun7qqrfh38lkj
21 Oct 21
Departure of Directors or Certain Officers
5:02pm
8-K
hdh0qb 1hch7m
21 Oct 21
Regulation FD Disclosure
6:02am